Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei

European Journal of Immunology

Volumn 38, Issue 3, 2008, Pages 732-741

  Reyes Sandoval, Arturo ^a   Sridhar, Saranya ^a   Berthoud, Tamara ^b   Moore, Anne C ^a   Harty, John T ^c   Gilbert, Sarah C ^a   Gao, Guangping ^d   Ertl, Hildegund C J ^e   Wilson, James C ^d   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e WISTAR INSTITUTE   (United States)

Author keywords

CD8+ T cells; Malaria vaccine; Poxviral vectors; Simian adenoviral vectors

Indexed keywords

ADENOVIRUS VECTOR; ADENOVIRUS VECTOR C6; ADENOVIRUS VECTOR C7; ADENOVIRUS VECTOR C9; GAMMA INTERFERON; HUMAN ADENOVIRUS VACCINE; INTERLEUKIN 2; MALARIA VACCINE; ME STRING THROMBOSPONDIN; POXVIRUS VECTOR; SUBUNIT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR; CYTOKINE; DNA VACCINE; EPITOPE; GRANZYME; GZMB PROTEIN, MOUSE; LEUKOCYTE ANTIGEN; PROTOZOAL PROTEIN; THROMBOSPONDIN RELATED ADHESIVE PROTEIN, PROTOZOAN; THROMBOSPONDIN-RELATED ADHESIVE PROTEIN, PROTOZOAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; LOW DRUG DOSE; MALARIA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SIMIAN VIRUS; SINGLE DRUG DOSE; VIRUS PARTICLE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CYTOLOGY; GENE VECTOR; GENETICS; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; POXVIRUS; SPLEEN; SURVIVAL; T LYMPHOCYTE SUBPOPULATION;

ADENOVIRUSES, SIMIAN; ANIMALS; ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC VECTORS; GRANZYMES; INJECTIONS, INTRADERMAL; INTERFERON TYPE II; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLASMODIUM BERGHEI; POXVIRIDAE; PROTOZOAN PROTEINS; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS; VACCINES, DNA;

EID: 43649106615     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737672     Document Type: Article

References (34)

1. Snow, R. W., Guerra, C. A., Noor, A, M., Myint, H. Y. and Hay, S. I., The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005. 434: 214-217.
2. Rowe, A. K., Rowe, S. Y., Snow, R. W., Korenromp, E. L., Schellenberg, J. R., Stein, C., Nahlen, B. L. et al., The burden of malaria mortality among African children in the year 2000. Int. J. Epidemiol. 2006. 35: 691-704.
3. Hill, A. V., Pre-erythrocytic malaria vaccines: Towards greater efficacy. Nat. Rev. Immunol. 2006. 6: 21-32.
4. Tsuji, M. and Zavala, F., T cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol. 2003. 19: 88-93.
5. Khusmith, S., Charoenvit, Y., Kumar, S., Sedegah, M., Beaudoin, R. L. and Hoffman, S. L., Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 1991. 252: 715-718.
6. Moorthy, V. S., McConkey, S., Roberts, M., Gothard, P., Arulanantham, N., Degano, P., Schneider, J. et al., Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003. 21: 1995-2002.
7. Webster, D. P., Dunachie, S., Vuola, J. M., Berthoud, T., Keating, S., Laidlaw, S. M., McConkey, S. J. et al., Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. USA 2005. 102: 4836-4841.
8. + T cell-mediated protective immunity against malaria. J. Immunol. 1997. 158: 1268-1274.
9. Chirmule, N., Propert, K., Magosin, S., Qian, Y., Qian, R. and Wilson, J., Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999. 6: 1574-1583.
10. Tatsis, N. and Ertl, H. C., Adenoviruses as vaccine vectors. Mol. Ther. 2004. 10: 616-629.
11. Zhi, Y., Figueredo, J., Kobinger, G. P., Hagan, H., Calcedo, R., Miller, J. R., Gao, G. and Wilson, J. M., Efficacy of severe acute respiratory syndrome vaccuie based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum. Gene Ther. 2006. 17: 500-506.
12. Fitzgerald, J. C., Gao, G. P., Reyes-Sandoval, A., Pavlakis, G. N., Xiang, Z. Q., Wlazlo, A. P., Giles-Davis, W. et al., A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 2003. 170: 1416-1422.
13. Reyes-Sandoval, A., Fitzgerald, J. C., Grant, R., Roy, S., Xiang, Z. Q., Li, Y., Gao, G. P. et al., Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J. Virol. 2004. 78: 7392-7399.
14. Xiang, Z., Gao, G., Reyes-Sandoval, A., Cohen, C. J., Li, Y., Bergelson, J. M., Wilson, J. M. and Ertl, H. C., Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 2002. 76: 2667-2675.
15. Harrington, L. E., Galvan, M., Baum, L. G., Altman, J. D. and Ahmed, R., Differentiating between memory and effector CD8 T cells by altered expression of cell surface. O-glycans. J. Exp. Med. 2000. 191: 1241-1246.
16. + T cells. J. Exp. Med. 2004. 199: 925-936.
17. + T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 2005. 11: 748-756.
18. - T cells. Eur. J. Immunol. 2005. 35: 3131-3141.
19. + T cells. Blood 2006. 107: 4781-4789.
20. Romero, P., Maryanski, J. L., Corradin, G., Nussenzweig, R. S., Nussenzweig, V. and Zavala, F., Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989. 341: 323-326.
21. Gilbert, S. C., Schneider, J., Hannan, C. M., Hu, J. T., Plebanski, M., Sinden, R. and Hill, A. V., Euhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002. 20: 1039-1045.
22. Shiver, J. W., Fu, T. M., Chen, L., Casimiro, D. R., Davies, M. E., Evans, R. K., Zhang, Z. Q. et al., Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002. 415: 331-335.
23. Catanzaro, A. T., Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L. et al., Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 2006. 194: 1638-1649.
24. + T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J. Immunol. 2005. 175; 4686-4696.
25. Tatsis, N., Fitzgerald, J. C.. Reyes-Sandoval, A., Harris-McCoy, K. C., Hensley, S. E., Zhou, D., Lin, S. W. et al., Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: Implications for their use as vaccines. Blood 2007. 110: 1916-1923.
26. Wherry, E. J., Teichgraber, V., Becker, T. C., Masopust, D., Kaech, S. M., Antia, R., von Andrian, U. H. and Ahmed, R., Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 2003. 4: 225-234.
27. Keating, S. M., Bejon, P., Berthoud, T., Vuola, J. M., Todryk, S., Webster, D. P., Dunachie, S. J. et al., Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 2005. 175: 5675-5680.
28. Casimiro, D. R., Chen, L., Fu, T. M., Evans, R. K., Caulfield, M. J., Davies, M. E., Tang, A. et al., Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 2003. 77: 6305-6313.
29. Lemckert, A. A., Sumida, S. M., Holterman, L., Vogels, R., Truitt, D. M., Lynch, D. M., Nanda, A. et al., Immunogenicity of heterologous primeboost regimens involving mombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-Ad5 immunity. J. Virol. 2005. 79: 9694-9701.
30. Gilbert, S. C., Plebanski, M., Harris, S. J., Allsopp, C. E., Thomas, R., Layton, G. T. and Hill, A. V., A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 1997, 15: 1280-1284.
31. McConkey, S. J., Reece, W. H., Moorthy, V. S., Webster,,D., Dunachie, S., Butcher, G., Vuola, J. M. et al., Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in human. Nat. Med. 2003, 9; 729-735.
32. Roy, S., Gao, G., Lu., Y., Zhou, X., Lock, M., Calcedo, R. and Wilson, J. M., Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum. Gene Ther. 2004. 15: 519-530.
33. Moore, A. C., Gallimore, A., Draper, S. J., Watkins, K. R., Gilbert, S. C. and Hill, A. V., Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: Increased durable cellular immunity with reduced immunodominance. J. Immunol. 2005. 175: 7264-7273.
34. + T cells are more protective but slower to acquire a central-memory phenotype. J. Exp. Med. 2006. 203: 919-932.